Table 2.

ALLHAT Findings in Participants with the Metabolic Syndrome

	RR (95% CI) vs. Diuretic
	Non Fatal MI / Fatal CHD	All-Cause Mortality	CCHD	Stroke	HF	CCVD	ESRD
Participants without MetS
α-Blocker	1.00 (0.82-1.22)	0.99 (0.86-1.15)	1.14 (0.99-1.31)	1.19 (0.92-1.55)	1.91 (1.53-2.38)	1.17 (1.05-1.29)	0.81 (0.44-1.49)
ACEI	1.02 (0.88-1.20)	1.02 (0.91-1.14)	1.07 (0.96-1.21)	1.20 (0.97-1.48)	1.02 (0.83-1.25)	1.07 (0.98-1.17)	0.76 (0.48-1.21)
CCB	1.05 (0.90-1.22)	0.93 (0.83-1.04)	1.03 (0.92-1.16)	1.04 (0.83-1.29)	1.45 (1.20-1.75)	1.05 (0.96-1.15)	0.81 (0.51-1.26)
Participants with MetS
α-Blocker	1.11 (0.96-1.28)	1.08 (0.95-1.22)	1.06 (0.96-1.17)	1.31 (1.08-1.58)	1.83 (1.57-2.14)	1.23 (1.14-1.33)	1.18 (0.79-1.77)
ACEI	1.01 (0.90-1.13)	1.01 (0.93-1.12)	1.04(0.96-1.14)	1.09 (0.93-1.28)	1.28 (1.12-1.47)	1.14 (1.06-1.21)	1.22 (0.92-1.63)
CCB	0.95 (0.84-1.07)	0.97 (0.88-1.06)	1.00(0.92-1.04)	0.87 (0.74-1.04)	1.32 (1.15-1.51)	1.05 (0.98-1.12)	1.27 (0.96-1.68)
Non-diabetic Participants with MetS
α-Blocker	1.15 (0.91-1.44)	1.10 (0.89-1.36)	1.07 (0.92-1.25)	1.34 (0.97-1.84)	1.86 (1.44-2.41)	1.24 (1.10-1.39)	0.86 (0.40-1.83)
ACEI	1.05 (0.88-1.27)	1.04 (0.89-1.22)	1.04(0.89-1.22)	1.22 (0.94-1.58)	1.31 (1.04-1.64)	1.19 (1.07-1.32)	1.08 (0.61-1.91)
CCB	0.96 (0.79-1.16)	0.98 (0.83-1.15)	1.01(0.88-1.15)	0.84 (0.62-1.13)	1.09 (0.85-1.38)	1.03 (0.92-1.14)	0.69 (0.36-1.36)
Black Participants with MetS
α-Blocker	1.18 (0.87-1.58)	1.09 (0.87-1.35)	1.15 (0.93-1.41)	1.49 (1.09-2.03)	1.88 (1.42-2.47)	1.37 (1.19-1.58)	1.17 (0.62-2.22)
ACEI	1.17 (0.95-1.47)	1.14 (0.97-1.34)	1.19 (1.01-1.40)	1.37 (1.07-1.76)	1.49 (1.17-1.90)	1.24 (1.09-1.40)	1.70 (1.13-2.55)
CCB	0.96 (0.76-1.21)	1.02 (0.86-1.20)	1.09 (0.92-1.29)	1.01 (0.77-1.33)	1.50 (1.18-1.90)	1.14 (1.00-1.29)	1.50 (0.99-2.28)